Lonza buys Capsugel for $5.5 billion
( December 15, 2016, 20:00 GMT | Official Statement) -- MLex Summary: Lonza Group has agreed to purchase US drug capsule maker Capsugel from KKR & Co. for $5.5 billion, as the Swiss biotech company seeks to bolster its healthcare business. The acquisition would make Lonza the "partner of choice" for drugmakers bringing new medicines to market, the companies said in a joint statement. The purchase price includes refinancing Capsugel's existing debt of about $2 billion.See attached full text of joint statement....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.